Skip to main content

Gentian Diagnostics

Gentian Diagnostics AS is a Norwegian in vitro diagnostics company headquartered in Moss, Norway. The firm develops and manufactures high-turbidimetric diagnostic tests based on proprietary nanoparticle technology. Its product portfolio includes diagnostic immunoassay reagents used to detect specific biomarkers for kidney disease, inflammatory conditions, and infectious diseases. Revenue is primarily generated through the sale of diagnostic reagent kits and bulk reagents to global clinical laboratory customers and instrument manufacturers. The company collaborates with international diagnostic partners to enable reagent integration across automated laboratory analyzers. Gentian Diagnostics AS is listed on the Oslo Stock Exchange.

6 of the funds FundTelligence covers report a position in Gentian Diagnostics.

Legal name
Gentian Diagnostics AS
Sector
Health Care
Country
Norway
Funds holding it
6

Funds holding Gentian Diagnostics

  • Delphi Norge — Storebrand · 1.67 % (full portfolio disclosed, October 2026)
  • Schroder ISF Nordic Micro Cap — Schroders · 1.4 % (full portfolio disclosed, June 2026)
  • Delphi Nordic — Storebrand · 0.4 % (full portfolio disclosed, October 2026)
  • Storebrand Vekst — Storebrand · 0.35 % (full portfolio disclosed, October 2026)
  • DNB SMB — DNB · 0.24 % (full portfolio disclosed, September 2026)
  • Delphi Kombinasjon — Storebrand · 0.2 % (full portfolio disclosed, October 2026)

Loading...